Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Deloitte Predicts Pharma Growth Driven by Orphan Disease Drugs and External Deals

Global healthcare spending is expected to increase dramatically to more than $10 trillion by 2022, driven primarily by an increase in spending on data that will increase value and create a sustainable culture.

Read More »

Indivior launches generic version of own opioid drug

Indivior launched a copycat version of the opioid addiction drug Suboxone in the U.S., one day after a court decision cleared the way for rivals to market generic forms of the blockbuster medicine.

Read More »

Intercept’s fatty liver drug meets late-stage main goal

Intercept Pharmaceuticals Inc. said the treatment obeticholic acid (OCA) showed an improvement in scarring on the organ in patients with a progressive fatty liver disease.

Read More »

Antipsychotic Rexulti Fails Two Bipolar Phase III Trials

Denmark’s H. Lundbeck and Japan’s Otsuka Pharmaceutical announced that the antipsychotic drug Rexulti (brexpiprazole) failed to meet the primary endpoint in two Phase III clinical studies to treat manic episodes in patients with bipolar I disorder.

Read More »

Teva Pharmaceutical sees weaker than expected 2019

Teva Pharmaceutical Industries forecast lower revenue and profit for 2019, missing analysts’ expectations, as the company faces generic competition for two key branded drugs.

Read More »

Top 10 Pipelines To Watch: 2019 Annual Report

The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.

Read More »

Gilead misses key goal in NASH liver disease trial, shares sink

Gilead Sciences Inc. said a late-stage study for selonsertib aimed at treating the progressive fatty liver disease NASH failed to meet the key experimental drug’s main goal, sending the company’s shares down 4.6 percent.

Read More »

Eli Lilly backs U.S. proposal on drug rebates to lower costs

Eli Lilly embraced a U.S. government proposal to end a decades-old system of rebates drugmakers make to industry middlemen.

Read More »

GSK, Merck KGaA ink cancer immunotherapy deal

GlaxoSmithKline bolstered the company’s cancer drug development pipeline, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Merck KGaA for the rights to a next-generation immunotherapy.

Read More »

Roche adapts newer breast cancer drug in face of Herceptin imitations

Roche aims to broaden the use of the Swiss drugmaker’s Kadcyla breast cancer treatment as rivals crowd into the market with biosimilar copies of the company’s older mainstay product Herceptin.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom